Molbio Diagnostics prepares for IPO in FY25 to boost Rs 2,200-2,400 crore | IPO Information

Goa-based diagnostics chain Molbio Diagnostics, backed by Temasek and Motilal Oswal Non-public Fairness (MOPE), is ready to launch an preliminary public providing (IPO) within the monetary 12 months 2025, in response to reviews.

The corporate goals to boost between Rs 2,200 crore and Rs 2,400 crore, in response to Moneycontrol’s report.

Enterprise Normal was not in a position to independently confirm this. Molbio Diagnostics didn’t reply to feedback.

Molbio Diagnostics, led by technocrat and CEO Sriram Natarajan, is famend for its Truenat know-how—a point-of-care, moveable, battery-operated real-time PCR platform. Truenat is recognised by the World Well being Group (WHO) as a substitute for smear microscopy in diagnosing tuberculosis.

Molbio’s future plans embody strengthening diagnostic testing for hepatitis C, B, HPV, and HIV, along with tuberculosis. The corporate can also be growing point-of-care applied sciences in haematology, most cancers, antimicrobial resistance, next-generation sequencing, and syndromic testing.

Molbio reported a income of Rs 850 crore for FY24 and goals to extend this to Rs 1,200 crore in FY25 by increasing its international presence and launching new merchandise within the Indian market. In February 2023, Molbio acquired a majority stake in Prognosys Medical Methods, a producer of digital X-ray machines, marking its entry into the radiology phase.

First Revealed: Could 31 2024 | 4:40 PM IST